Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Alabama
-
Jasper, Alabama, Stati Uniti, 35501
- Pulmonary & Sleep Associates of Jasper, PC
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85006
- Pulmonary Associates, PA
-
Tucson, Arizona, Stati Uniti, 85712
- Arizona Clinical Research Center, Inc.
-
-
California
-
Fair Oaks, California, Stati Uniti, 95628
- Northern California Research Corp.
-
Fresno, California, Stati Uniti, 93720
- SARC Research Center
-
Fullerton, California, Stati Uniti, 92835
- California Research Medical Group, Inc.
-
Irvine, California, Stati Uniti, 92618
- Radiant Research-Irvine
-
Newport Beach, California, Stati Uniti
- West Coast Clinical Trials
-
Paramount, California, Stati Uniti, 90723
- Center for Clinical Trials, LLC
-
Rancho Mirage, California, Stati Uniti, 92270
- Advances in Medicine
-
San Diego, California, Stati Uniti, 92120
- Institute of HealthCare Assessment, Inc.
-
San Jose, California, Stati Uniti
- San Jose Clinical Research
-
Walnut Creek, California, Stati Uniti, 94598
- Allergy & Asthma Medical Group of Diablo Valley, Inc.
-
-
Colorado
-
Denver, Colorado, Stati Uniti, 80218
- Colorado Pulmonary Associates
-
Fort Collins, Colorado, Stati Uniti
- Northern Colorado Pulmonary Consultants, PC
-
-
Connecticut
-
Hartford, Connecticut, Stati Uniti, 06106
- Physicians Research Center, Inc.
-
-
District of Columbia
-
Washington, District of Columbia, Stati Uniti
- Washington Hospital Center
-
-
Florida
-
Clearwater, Florida, Stati Uniti, 33765
- Clinical Research of West Florida, Inc.
-
DeLand, Florida, Stati Uniti, 32720
- University Clinical Research, DeLand
-
Miami Beach, Florida, Stati Uniti, 33140
- Mt. Sinai Medical Center
-
Tampa, Florida, Stati Uniti, 33617
- Clinical Pharmacology Services
-
-
Georgia
-
Austell, Georgia, Stati Uniti, 30106
- Protocare Trial, Inc.
-
Marietta, Georgia, Stati Uniti, 30060
- Marietta Pulmonary Medicine
-
-
Illinois
-
O'Fallon, Illinois, Stati Uniti, 62269
- Office of Bradley Sakran, MD, PC
-
-
Indiana
-
South Bend, Indiana, Stati Uniti, 46617
- South Bend Clinic
-
-
Kentucky
-
Louisville, Kentucky, Stati Uniti, 40215
- Family Allergy & Asthma Research Institute
-
Somerset, Kentucky, Stati Uniti
- Cumberland Lung and Sleep Specialists
-
-
Louisiana
-
Lafayette, Louisiana, Stati Uniti, 70503
- Bendel Medical Associates/Research
-
New Orleans, Louisiana, Stati Uniti
- New Orleans Center for Clinical Research
-
New Orleans, Louisiana, Stati Uniti, 70119
- New Orleans Center for Clinical Research
-
New Orleans, Louisiana, Stati Uniti, 70115
- Best Clinical Trials, LLC
-
Slidell, Louisiana, Stati Uniti, 70461
- North Shore Research Associates
-
Sunset, Louisiana, Stati Uniti, 70584
- Sunset Medical Research
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti
- University of Maryland-Airways Research Center
-
Wheaton, Maryland, Stati Uniti
- Institute of Asthma and Allergy
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02135
- Pro-Medica Clinical Research Center
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48106
- ClinSite, Inc.
-
-
Missouri
-
Saint Louis, Missouri, Stati Uniti, 63108
- Medex Healthcare Research, Inc.
-
St. Charles, Missouri, Stati Uniti, 63301-2847
- Midwest Chest Consultants, PC
-
St. Louis,, Missouri, Stati Uniti, 63122
- C.A.R.E Clinical Research
-
-
Montana
-
Butte, Montana, Stati Uniti
- Office of Keith Popovich, MD
-
Missoula, Montana, Stati Uniti
- Montana Medical Research, LLC
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti
- VA Medical Center
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89119
- Advanced Biomedical Research of America
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27599
- Pulmonary Medicine
-
Charlotte, North Carolina, Stati Uniti, 28207
- Charlotte Lung and Health Center
-
Statesville, North Carolina, Stati Uniti, 28625
- Carolina Pharmaceutical Research, Inc.
-
Wilmington, North Carolina, Stati Uniti, 28412
- New Hanover Medical Research
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45241
- New Horizons Clinical Research, Inc.
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73103
- COR Clinical Research LLC
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97213
- Allergy Associates Research Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18104
- Northeast Clinical Research Centers, Inc.
-
Altoona, Pennsylvania, Stati Uniti, 16602
- Keystone Clinical Solutions
-
Philadelphia, Pennsylvania, Stati Uniti, 19146
- Philadelphia Health Associates - Adult Medicine
-
Ridley Park, Pennsylvania, Stati Uniti, 19078
- Consortium Clinical Research, Ltd.
-
-
Rhode Island
-
East Providence, Rhode Island, Stati Uniti, 02914
- Safe Harbor Clinical Research
-
-
South Carolina
-
Spartanburg, South Carolina, Stati Uniti, 29307
- Spartanburg Pharmaceutical Research
-
-
Tennessee
-
Knoxville, Tennessee, Stati Uniti, 37920
- Volunteer Research Group
-
-
Texas
-
Houston, Texas, Stati Uniti, 77084
- Breath of Life Research Institute
-
New Braunfels, Texas, Stati Uniti, 78130
- Central Texas Health Research
-
San Antonio, Texas, Stati Uniti, 78229
- Sylvana Research Associates
-
-
Virginia
-
Fredericksburg, Virginia, Stati Uniti, 22401
- Pulmonary Associates of Fredericksburg, Inc.
-
Richmond, Virginia, Stati Uniti, 23225
- Pulmonary Associates of Richmond, Inc.
-
-
Washington
-
Bellingham, Washington, Stati Uniti, 98225
- Bellingham Asthma, Allergy & Immunology Clinic
-
-
Wisconsin
-
Madison, Wisconsin, Stati Uniti, 53792
- University of Wisconsin-Medical School
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Be willing to comply with study procedures and visit schedule
- Are at least 35 years of age
- Female subjects >65 years of age must have a serum pregnancy test conducted at Visit 1 and confirmed negative prior to randomization
- Subjects of childbearing potential must be using an acceptable method of birth control. Female subjects who are considered not of childbearing potential must be: documented surgically sterile, OR postmenopausal.
- Have a primary diagnosis of COPD. Diagnosis can be made during the screening process.
- Have a minimum smoking history of 15 pack-years (pack-years = the number of cigarette packs per day times the number of years).
- Have a chest x-ray that is consistent with the diagnosis of COPD and taken <3 months prior to study start
- Able to complete all study questionnaires and logs reliably
Exclusion Criteria:
- Female subject who is pregnant or lactating
- Have participated in an investigational drug study within 30 days prior to study start, or who is currently participating in another investigational drug study
- Subject whose schedule or travel prevents the completion of all required visits
- Are scheduled for in-patient hospitalization, including elective surgery during the trial
- Have life-threatening/unstable respiratory status, including upper or lower respiratory tract infection, within the previous 30 days
- History of asthma or any chronic respiratory disease other than COPD (chronic bronchitis and/or emphysema)
- Have clinically significant cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol
- Have a history of cancer except non-melanomatous skin cancer
- Have a history of lung resection of more than one full lobe
- Requires continuous supplemental oxygen therapy.
- Has had a change in dose or type of any medications for COPD within 14 days prior to the screening visit
- Have a known sensitivity to arformoterol, ipratropium, salmeterol or albuterol or any of the excipients contained in any of these formulations
- Have a history of substance abuse or drug abuse within 12 months, or with a positive urine drug screen
- Are using any prescription drug for which concomitant beta-agonist administration is contraindicated (e.g., beta-blockers)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: 1
Arformoterol 50 mcg QD and placebo MDI
|
arformoterol 50 mcg QD
Altri nomi:
arformoterol 25 mcg BID
Altri nomi:
arformoterol 15 mcg BID
Altri nomi:
|
|
Sperimentale: 2
Arformoterol 25 mcg BID and Placebo MDI
|
arformoterol 50 mcg QD
Altri nomi:
arformoterol 25 mcg BID
Altri nomi:
arformoterol 15 mcg BID
Altri nomi:
|
|
Sperimentale: 3
Arformoterol 15 mcg BID and placebo MDI
|
arformoterol 50 mcg QD
Altri nomi:
arformoterol 25 mcg BID
Altri nomi:
arformoterol 15 mcg BID
Altri nomi:
|
|
Comparatore attivo: 4
Salmeterol MDI 42 mcg BID and placebo inhalation solution
|
Salmeterol MDI 42 mcg BID
Altri nomi:
|
|
Comparatore placebo: 5
Placebo MDI and placebo inhalation solution
|
OFFERTA Placebo
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period.
Lasso di tempo: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Percentuale di picco del FEV1 previsto
Lasso di tempo: Settimane -2, 0, 3, 6, 9, 12
|
Settimane -2, 0, 3, 6, 9, 12
|
|
time-normalized area under the percent change from visit predose curve for FEV1 over 12 hours (nAUC0-12-P)
Lasso di tempo: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
|
time-normalized area under the percent change in FEV1 from study baseline over 12 hours (nAUC0-12-B)
Lasso di tempo: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
|
time-normalized area under the percent change from visit predose curve for FEV1 over 24 hours (nAUC0-24-P)
Lasso di tempo: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
|
time-normalized area under the percent change in FEV1 from study baseline curve over 24 hours (nAUC0-24-B)
Lasso di tempo: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
|
peak percent change in FEV1 from visit predose and study baseline
Lasso di tempo: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
|
time point changes in FEV1; time to onset of response
Lasso di tempo: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
|
time to peak change in FEV1
Lasso di tempo: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
|
at-home and in-clinic peak expiratory flow rate (PEFR)
Lasso di tempo: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
|
relationship between the plasma concentration values and selected pharmacodynamic parameters
Lasso di tempo: Weeks -2, 0, 3, 6, 9, 12, 13
|
Weeks -2, 0, 3, 6, 9, 12, 13
|
|
Supplemental ipratropium bromide MDI and racemic albuterol MDI use
Lasso di tempo: Weeks 0-13
|
Weeks 0-13
|
|
COPD exacerbations and COPD symptom ratings
Lasso di tempo: Weeks 0-13
|
Weeks 0-13
|
|
St. George's Hospital Respiratory Questionnaire
Lasso di tempo: Weeks 0, 6, 13
|
Weeks 0, 6, 13
|
|
Investigator and Subject Global Evaluations
Lasso di tempo: Weeks -2, 12, 13
|
Weeks -2, 12, 13
|
|
Baseline and Transitional Dyspnea Index
Lasso di tempo: Weeks -2, 6, 12
|
Weeks -2, 6, 12
|
|
distance walked in six minutes
Lasso di tempo: Weeks -2, 3, 9
|
Weeks -2, 3, 9
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Infezioni
- Infezioni delle vie respiratorie
- Malattie delle vie respiratorie
- Malattie bronchiali
- Malattie polmonari
- Malattie polmonari, ostruttive
- Malattia polmonare, cronica ostruttiva
- Enfisema
- Bronchite
- Bronchite, cronica
- Effetti fisiologici delle droghe
- Agenti adrenergici
- Agenti neurotrasmettitori
- Meccanismi molecolari dell'azione farmacologica
- Agenti autonomi
- Agenti del sistema nervoso periferico
- Agonisti adrenergici
- Agenti broncodilatatori
- Agenti antiasmatici
- Agenti del sistema respiratorio
- Agonisti del recettore adrenergico beta-2
- Beta-agonisti adrenergici
- Soluzioni farmaceutiche
- Salmeterolo Xinafoato
- Formoterolo fumarato
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 091-051
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .